source
- GSK, Hansoh ADC extends survival in lung cancer studyGSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.BioPharma Dive · 1mo ago↗ source
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.BioPharma Dive · 1mo ago↗ source
- Roche scraps two Ionis-partnered Huntington’s drugsThe Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.